Seeking Alpha

Eli Lilly (LLY) says it's diagnostic radiopharmaceutical Amyvid has received marketing...

Eli Lilly (LLY) says it's diagnostic radiopharmaceutical Amyvid has received marketing authorization from the European Commission for Positron Emission Tomography imaging of beta-amyloid neuritic plaque density in the brains of adult patients with Alzheimer's Disease and other forms of cognitive impairment.
Comments (1)
  • Tony Petroski
    , contributor
    Comments (6373) | Send Message
     
    Now, my attorney confirms that the:

     

    "European Commission for Positron Emission Tomography"

     

    is instead, a front-group for these guys

     

    "The European Positron Tomograhy Euro Commission for the Commission of Positron Emissions Tomography Eliminations Group (Under study by...)

     

    (sigh)

     

    (now that you mention it, it can't be easy feeding fat cats these days)

     

    Prove me and my attorney wrong!
    15 Jan 2013, 04:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|